文献速递产科

阴道分娩后预防性缩宫素剂量预防产后出血:系统综述与剂量反应Meta分析

Prophylactic oxytocin dose following vaginal birth to prevent postpartum hemorrhage: a systematic review and dose-response meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2025-09-24

该系统综述与剂量反应Meta分析纳入13项随机对照试验共8961名参与者,评估阴道分娩后不同缩宫素预防剂量对产后出血的影响。结果显示,预防性缩宫素剂量与出血≥1000 mL、平均失血量及额外使用宫缩剂呈J型非线性关系,4至10 IU剂量在疗效与安全性间平衡最佳。作者指出证据基础存在剂量范围窄、高风险人群代表性不足及安全性结局报告不一致等局限,需进一步研究。

要点

  • 预防性缩宫素4至10 IU可使每1000人中出血≥1000 mL者减少6至7例(高确定性)。
  • 4至10 IU可能使每100人中需额外宫缩剂者减少10至12例(中等确定性)。
  • 较低剂量2.5至3 IU可能降低严重失血风险(中等确定性),并可能减少额外宫缩剂使用(低确定性)。

核心结论

  • 现有证据提示阴道分娩后预防性缩宫素的最佳范围为4至10 IU,该范围内较低剂量在疗效与安全性间平衡最佳。
  • 证据基础存在局限,包括剂量范围窄、高风险人群代表性不足及安全性结局报告不一致,需在不同临床情境中进一步研究。

研究设计与样本

  • 系统综述与剂量反应Meta分析,纳入比较不同静脉或肌内预防性缩宫素剂量、或单次预防性剂量与无缩宫素的随机对照试验。
  • 检索MEDLINE、Embase、CINAHL、Web of Science、Global Health、Cochrane Central Register of Controlled Trials及ClinicalTrials.gov(自建库至2025年6月9日),并检索合格试验的参考文献列表。
  • 共纳入13项研究,涉及8961名参与者,缩宫素剂量范围为2.5至80 IU。
  • 采用随机效应剂量反应Meta分析,单阶段方法,限制性最大似然异质性估计,并使用限制性立方样条建模检测非线性。
  • 使用推荐分级的评估、制定与评价(GRADE)方法评估证据确定性。

主要发现

  • 出血≥1000 mL、平均失血量和额外使用宫缩剂呈J型非线性关系。
  • 4至10 IU剂量使每1000人中出血≥1000 mL者减少6至7例(高确定性;无缩宫素时风险为每1000人19例)。
  • 4至10 IU剂量可能使每100人中需额外宫缩剂者减少10至12例(中等确定性;无缩宫素时风险为每100人26例),但平均失血量可能几乎无差异(中等确定性)。
  • 较低剂量(2.5至3 IU)可能降低严重失血风险(中等确定性),并可能减少额外宫缩剂使用(低确定性)。
  • 20 IU时严重失血风险可能降低(中等确定性),更高剂量效益可能递减(低确定性);剂量≥20 IU时额外宫缩剂可能增加(低确定性);输血未见剂量反应关系。

关键数值与推荐

  • 出血≥1000 mL:4至10 IU较无缩宫素每1000人减少6至7例(高确定性)。
  • 额外使用宫缩剂:4至10 IU较无缩宫素每100人减少10至12例(中等确定性)。
  • 平均失血量:4至10 IU较无缩宫素可能几乎无差异(中等确定性)。
  • 严重失血:2.5至3 IU可能降低风险(中等确定性),20 IU可能降低风险(中等确定性)。
  • 额外宫缩剂:剂量≥20 IU时可能增加(低确定性)。

临床怎么用

  • 作者认为阴道分娩后预防性缩宫素的最佳范围为4至10 IU,该范围内较低剂量在疗效与安全性间平衡最佳。
  • 作者指出证据基础存在局限,需在不同临床情境中进一步研究。

局限性

  • 证据基础存在局限,包括剂量范围窄。
  • 高风险人群代表性不足。
  • 安全性结局报告不一致。
  • 需在不同临床情境中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A systematic review and dose-response meta-analysis assessing the effect of different oxytocin prophylaxis doses on preventing postpartum hemorrhage after vaginal birth. DATA SOURCES: MEDLINE, Embase, CINAHL, Web of Science, Global Health, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov (inception-June 9, 2025), along with reference lists of eligible trials. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials comparing different intravenous or intramuscular doses of prophylactic oxytocin, or a single prophylactic dose with no oxytocin, following vaginal birth were included. STUDY APPRAISAL AND SYNTHESIS METHODS: Two authors independently evaluated studies for inclusion and risk of bias. A random-effects dose-response meta-analysis was conducted using a one-stage approach with a restricted maximum likelihood heterogeneity estimator and modeled using restricted cubic splines to detect departure from linearity. Certainty of evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluation methodology. Sufficient data were available to undertake a dose-response meta-analysis for blood loss ≥1000 mL, mean blood loss, blood transfusion, and use of additional uterotonics. RESULTS: 13 studies involving 8961 participants were included, with oxytocin doses ranging from 2.5 to 80 IU. A J-shaped, nonlinear relationship was observed for blood loss ≥1000 mL, mean blood loss, and use of additional uterotonics. Doses of 4 to 10 IU resulted in 6 to 7 fewer individuals per 1000 experiencing blood loss ≥1000 mL (high certainty; risk with no oxytocin: 19 per 1000 individuals), likely 10 to 12 fewer individuals per 100 requiring additional uterotonics (moderate certainty; risk with no oxytocin: 26 per 100 individuals), but likely resulted in little to no difference in mean blood loss (moderate certainty). Lower doses (2.5-3 IU) likely reduced the risk of severe blood loss (moderate certainty) and may reduce additional uterotonic use (low certainty). At 20 IU, the risk of severe blood loss was probably reduced (moderate certainty), with possible diminishing returns at higher doses (low certainty). Additional uterotonics may increase at doses ≥20 IU (low certainty). No dose-response relationship was observed for blood transfusion. CONCLUSION: Available evidence suggests the optimal range for oxytocin prophylaxis after vaginal birth is 4 to 10 IU, with lower doses within this range offering the best balance of efficacy and safety. However, limitations in the evidence base, including narrow dose ranges, under-representation of high-risk populations, and inconsistent reporting of safety outcomes, highlight the need for further research across clinical contexts.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Hébert V, D'Souza R, Santesso N, et al. Prophylactic oxytocin dose following vaginal birth to prevent postpartum hemorrhage: a systematic review and dose-response meta-analysis. Am J Obstet Gynecol. 2025. PMID: 41005452. doi:10.1016/j.ajog.2025.09.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。